search
Back to results

BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) (BELIEF)

Primary Purpose

Lung Cancer

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Erlotinib
Bevacizumab
Sponsored by
ETOP IBCSG Partners Foundation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lung Cancer focused on measuring non small cell lung cancer, advanced, non-squamous, EGFR, mutations

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years
  • ECOG performance status 0-2
  • Adequate haematological function, coagulation, liver function and renal function
  • Pathological diagnosis of predominantly non-squamous, non-small-cell lung cancer (NSCLC)
  • TNM version 7 stage IV disease including M1a (malignant effusion) or M1b (distant metastasis), or locally advanced disease not amenable to curative treatment (including patients progressing after radiochemotherapy for stage III disease)
  • Measurable or evaluable disease (according to RECIST 1.1 criteria).
  • Centrally confirmed EGFR exon 19 deletion (del19) or exon 21 mutation (L858R)

Exclusion Criteria:

  • Patients with increased risk of bleeding
  • Patients with clinically significant cardiovascular diseases
  • Patients with a history of thrombosis or thromboembolism in the 6 months prior to treatment
  • Patients with gastrointestinal problems
  • Patients with neurologic problems
  • Patients who have had in the past 5 years any previous or concomitant malignancy EXCEPT adequately treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, in situ breast carcinoma.
  • Patients with any known significant ophthalmologic anomaly of the ocular surface
  • Patients who received prior chemotherapy for metastatic disease
  • Patients who received previous treatment for lung cancer with drugs targeting EGFR or VEGF
  • Pregnancy

Sites / Locations

  • Centre Francois Baclesse
  • Hôpital de Marseille
  • Hospital Grosshansdorf
  • Thoraxklinik Heidelberg GmbH
  • Lungenklinik Hemer
  • Universitätsklinikum Ulm
  • University General Hospital of Heraklion
  • Papageorgias Hospital
  • St Vincent's University Hospital
  • St. James's Hospital
  • University Hospital Galway
  • Mid-Western Regional Hospital
  • AMCCH
  • Ospedale San Gerardo
  • Istituto Oncologico Veneto IRCCS
  • Casa di Cura Maddalena
  • Policlinico Tor Vergata Roma
  • San Camillo Hospital
  • Policlinico Umberto
  • Hospital General Universitario Alicante
  • ICO - Hospital Universitari Germans Trias i Pujol
  • Hospital De La Santa Creu I Sant Pau
  • Vall d'Hebron University Hospital
  • Hospital Clínic Barcelona
  • ICO - Girona
  • ICO - Hospital Duran i Reynals
  • Hospital Clinico Universitario San Carlos
  • Hospital 12 de Octubre
  • Hospital General de Valencia
  • Hospital La Fe
  • University Hospital Basel
  • Istituto Oncologica della Svizzera Italiana
  • Inselspital Bern
  • Geneva University Hospital
  • Fondation du centre Pluridisciplinaire d'Oncologie (CePO)
  • Kantonsspital Luzern
  • Kantonsspital St. Gallen
  • Onkologiezentrum Berner Oberland
  • Kantonsspital Winterthur
  • University Hospital Zurich
  • Mid Essex Hospital Services NHS Trust
  • Queen's Hospital
  • University Hospitals of Leicester
  • Royal Marsden Hospital
  • Kent Oncology Centre
  • Christie Hospital Manchester
  • Wythenshawe Hospital Manchester
  • Wrexham Maelor Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Erlotinib plus bevacizumab

Arm Description

Patients will be treated with erlotinib and bevacizumab. Bevacizumab: 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days) Erlotinib: 150 mg p.o., daily

Outcomes

Primary Outcome Measures

Progression Free Survival
Time from the date of enrollment until an investigator-documented progression or death, whichever occurs first. Assessment of Progressive Disease (PD) is based on Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1): at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum recorded on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Secondary Outcome Measures

Overall Survival
Time from the date of enrollment until death from any cause.
Time to Treatment Failure
Time from the date of enrollment to discontinuation of treatment for any reason including progression of disease (based on RECIST v1.1), treatment toxicity (adverse events classified according to NCI CTCAE version 4.), refusal and death.
Objective Response
Objective response is defined as best overall response (CR or PR) across all assessment time-points during the period from enrollment to termination of trial treatment. Objective response, along with progressive and stable disease, will be determined using RECIST 1.1 criteria: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Progression (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum recorded on the trial. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum of diameters recorded on the trial.
Disease Control
Disease control is defined as achieving objective response (CR or PR, across all time-points from enrollment to termination of trial treatment) or stable disease for at least 6 weeks. Objective response, along with SD (disease control) and PD (no disease control), will be determined using RECIST 1.1 criteria: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters.Progression (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum recorded on the trial. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum of diameters recorded on the trial.
Duration of Response
Interval from the date of first documentation of objective response (CR or PR) to the date of first documented progression or relapse. Assessment of Objective response and Progressive Disease (PD) is based on the RECIST 1.1 criteria: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Progression (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum recorded on the trial. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum of diameters recorded on the trial.
Adverse Events
Adverse events graded according to NCI CTCAE V4.

Full Information

First Posted
March 22, 2012
Last Updated
August 23, 2022
Sponsor
ETOP IBCSG Partners Foundation
Collaborators
Spanish Lung Cancer Group
search

1. Study Identification

Unique Protocol Identification Number
NCT01562028
Brief Title
BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)
Acronym
BELIEF
Official Title
An Open-label Phase II Trial of Erlotinib and Bevacizumab in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Completed
Study Start Date
June 2012 (undefined)
Primary Completion Date
October 31, 2018 (Actual)
Study Completion Date
October 31, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ETOP IBCSG Partners Foundation
Collaborators
Spanish Lung Cancer Group

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Rationale: Advanced non-small-cell lung cancer (NSCLC) patients harbouring epidermal growth factor receptor (EGFR) mutations (del19 or L858R) show an impressive progression-free survival between 9 and 14 months when treated with erlotinib. However, the presence of EGFR mutations can only imperfectly predict outcome. The investigators hypothesize that progression-free survival could be influenced both by the pretreatment EGFR T790M mutation and by components of DNA repair pathways. The investigators propose a model of treatment whereby patients with EGFR mutations (single or with T790M) can attain a benefit with longer overall PFS when treated with erlotinib plus bevacizumab. When the patients are grouped by BRCA1 mRNA levels and T790M the hypothesis is that the combination of erlotinib plus bevacizumab can improve the PFS in all subgroups.
Detailed Description
Objectives: To determine long-term outcome of patients with advanced non-squamous NSCLC harbouring EGFR mutations with or without T790M mutation at diagnosis and treated with the combination of erlotinib and bevacizumab. Primary endpoint: progression-free survival To evaluate the efficacy and tolerability of the combination To evaluate the correlation of BRCA1 mRNA and AEG-1 mRNA expression and T790M with progression-free survival To monitor EGFR mutations (including T790M) in serum and plasma longitudinally To evaluate molecular biomarkers related to EGFR TKI and bevacizumab Design: This is a multinational, multi-center phase II trial of erlotinib plus bevacizumab in patients with advanced non-squamous NSCLC harbouring EGFR mutations confirmed by central re-assessment. Patients will be stratified into two subgroups, with and without EGFR T790M mutation. The stratification will be done after the inclusion of patients. Sample size: 102 patients

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Cancer
Keywords
non small cell lung cancer, advanced, non-squamous, EGFR, mutations

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
109 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Erlotinib plus bevacizumab
Arm Type
Experimental
Arm Description
Patients will be treated with erlotinib and bevacizumab. Bevacizumab: 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days) Erlotinib: 150 mg p.o., daily
Intervention Type
Drug
Intervention Name(s)
Erlotinib
Other Intervention Name(s)
Tarceva (R) (Roche)
Intervention Description
Patients will be treated with erlotinib, 150 mg p.o., daily
Intervention Type
Drug
Intervention Name(s)
Bevacizumab
Other Intervention Name(s)
Avastin (R) Roche)
Intervention Description
Patients will be treated with bevacizumab 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days)
Primary Outcome Measure Information:
Title
Progression Free Survival
Description
Time from the date of enrollment until an investigator-documented progression or death, whichever occurs first. Assessment of Progressive Disease (PD) is based on Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1): at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum recorded on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time Frame
From the date of enrollment until documented progression or death, whichever occurs first, assessed up to 48 months.
Secondary Outcome Measure Information:
Title
Overall Survival
Description
Time from the date of enrollment until death from any cause.
Time Frame
From the date of enrollment until death, assessed up to 48 months.
Title
Time to Treatment Failure
Description
Time from the date of enrollment to discontinuation of treatment for any reason including progression of disease (based on RECIST v1.1), treatment toxicity (adverse events classified according to NCI CTCAE version 4.), refusal and death.
Time Frame
From the date of enrollment until discontinuation of treatment, assessed up to 48 months.
Title
Objective Response
Description
Objective response is defined as best overall response (CR or PR) across all assessment time-points during the period from enrollment to termination of trial treatment. Objective response, along with progressive and stable disease, will be determined using RECIST 1.1 criteria: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Progression (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum recorded on the trial. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum of diameters recorded on the trial.
Time Frame
Assessed across all time-points from enrollment to termination of trial treatment (max 48 months).
Title
Disease Control
Description
Disease control is defined as achieving objective response (CR or PR, across all time-points from enrollment to termination of trial treatment) or stable disease for at least 6 weeks. Objective response, along with SD (disease control) and PD (no disease control), will be determined using RECIST 1.1 criteria: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters.Progression (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum recorded on the trial. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum of diameters recorded on the trial.
Time Frame
Assessed across all time-points from enrollment to termination of trial treatment (max 48 months).
Title
Duration of Response
Description
Interval from the date of first documentation of objective response (CR or PR) to the date of first documented progression or relapse. Assessment of Objective response and Progressive Disease (PD) is based on the RECIST 1.1 criteria: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Progression (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum recorded on the trial. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum of diameters recorded on the trial.
Time Frame
Assessed across all time-points from enrollment to to the date of first documented progression or relapse (max 48 months).
Title
Adverse Events
Description
Adverse events graded according to NCI CTCAE V4.
Time Frame
Assessed across all time-points until end of treatment (30 +/-5 days following the last dose of study drug) (max 48 months).

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years ECOG performance status 0-2 Adequate haematological function, coagulation, liver function and renal function Pathological diagnosis of predominantly non-squamous, non-small-cell lung cancer (NSCLC) TNM version 7 stage IV disease including M1a (malignant effusion) or M1b (distant metastasis), or locally advanced disease not amenable to curative treatment (including patients progressing after radiochemotherapy for stage III disease) Measurable or evaluable disease (according to RECIST 1.1 criteria). Centrally confirmed EGFR exon 19 deletion (del19) or exon 21 mutation (L858R) Exclusion Criteria: Patients with increased risk of bleeding Patients with clinically significant cardiovascular diseases Patients with a history of thrombosis or thromboembolism in the 6 months prior to treatment Patients with gastrointestinal problems Patients with neurologic problems Patients who have had in the past 5 years any previous or concomitant malignancy EXCEPT adequately treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, in situ breast carcinoma. Patients with any known significant ophthalmologic anomaly of the ocular surface Patients who received prior chemotherapy for metastatic disease Patients who received previous treatment for lung cancer with drugs targeting EGFR or VEGF Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rafael Rosell, MD
Organizational Affiliation
Catalan Institute of Oncology, Hospital Germans Trias i Pujol
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Stahel Rolf, MD
Organizational Affiliation
Laboratory of Molecular Oncology, Clinic of Oncology, University Hospital Zuerich
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Miquel Taron
Organizational Affiliation
Medical Oncology Service-ICO, Hospital Germans Trias i Pujol
Official's Role
Study Chair
Facility Information:
Facility Name
Centre Francois Baclesse
City
Caen
ZIP/Postal Code
14000
Country
France
Facility Name
Hôpital de Marseille
City
Marseille
ZIP/Postal Code
13915
Country
France
Facility Name
Hospital Grosshansdorf
City
Grosshansdorf
ZIP/Postal Code
22927
Country
Germany
Facility Name
Thoraxklinik Heidelberg GmbH
City
Heidelberg
ZIP/Postal Code
69126
Country
Germany
Facility Name
Lungenklinik Hemer
City
Hemer
ZIP/Postal Code
58675
Country
Germany
Facility Name
Universitätsklinikum Ulm
City
Ulm
ZIP/Postal Code
89081
Country
Germany
Facility Name
University General Hospital of Heraklion
City
Heraklion
Country
Greece
Facility Name
Papageorgias Hospital
City
Thessaloniki
Country
Greece
Facility Name
St Vincent's University Hospital
City
Dublin
Country
Ireland
Facility Name
St. James's Hospital
City
Dublin
Country
Ireland
Facility Name
University Hospital Galway
City
Galway
Country
Ireland
Facility Name
Mid-Western Regional Hospital
City
Limerick
Country
Ireland
Facility Name
AMCCH
City
Tallaght
Country
Ireland
Facility Name
Ospedale San Gerardo
City
Monza
ZIP/Postal Code
20900
Country
Italy
Facility Name
Istituto Oncologico Veneto IRCCS
City
Padova
ZIP/Postal Code
35128
Country
Italy
Facility Name
Casa di Cura Maddalena
City
Palermo
ZIP/Postal Code
90146
Country
Italy
Facility Name
Policlinico Tor Vergata Roma
City
Roma
ZIP/Postal Code
00133
Country
Italy
Facility Name
San Camillo Hospital
City
Roma
ZIP/Postal Code
00151
Country
Italy
Facility Name
Policlinico Umberto
City
Roma
ZIP/Postal Code
00161
Country
Italy
Facility Name
Hospital General Universitario Alicante
City
Alicante
ZIP/Postal Code
03010
Country
Spain
Facility Name
ICO - Hospital Universitari Germans Trias i Pujol
City
Badalona
ZIP/Postal Code
08916
Country
Spain
Facility Name
Hospital De La Santa Creu I Sant Pau
City
Barcelona
ZIP/Postal Code
08025
Country
Spain
Facility Name
Vall d'Hebron University Hospital
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Hospital Clínic Barcelona
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
ICO - Girona
City
Girona
ZIP/Postal Code
17007
Country
Spain
Facility Name
ICO - Hospital Duran i Reynals
City
L'Hospitalet de Llobregat
ZIP/Postal Code
08907
Country
Spain
Facility Name
Hospital Clinico Universitario San Carlos
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Hospital 12 de Octubre
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Facility Name
Hospital General de Valencia
City
Valencia
ZIP/Postal Code
46014
Country
Spain
Facility Name
Hospital La Fe
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Facility Name
University Hospital Basel
City
Basel
ZIP/Postal Code
4031
Country
Switzerland
Facility Name
Istituto Oncologica della Svizzera Italiana
City
Bellinzona
ZIP/Postal Code
6650
Country
Switzerland
Facility Name
Inselspital Bern
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
Facility Name
Geneva University Hospital
City
Geneva
ZIP/Postal Code
1211
Country
Switzerland
Facility Name
Fondation du centre Pluridisciplinaire d'Oncologie (CePO)
City
Lausanne
ZIP/Postal Code
1011
Country
Switzerland
Facility Name
Kantonsspital Luzern
City
Luzern
ZIP/Postal Code
6016
Country
Switzerland
Facility Name
Kantonsspital St. Gallen
City
St. Gallen
ZIP/Postal Code
9007
Country
Switzerland
Facility Name
Onkologiezentrum Berner Oberland
City
Thun
ZIP/Postal Code
3600
Country
Switzerland
Facility Name
Kantonsspital Winterthur
City
Winterthur
ZIP/Postal Code
8401
Country
Switzerland
Facility Name
University Hospital Zurich
City
Zurich
ZIP/Postal Code
8091
Country
Switzerland
Facility Name
Mid Essex Hospital Services NHS Trust
City
Chelmsford
State/Province
Essex
ZIP/Postal Code
CM1 7ET
Country
United Kingdom
Facility Name
Queen's Hospital
City
Burton-upon-Trent
ZIP/Postal Code
DE13 0RB
Country
United Kingdom
Facility Name
University Hospitals of Leicester
City
Leicester
ZIP/Postal Code
LE1 5WW
Country
United Kingdom
Facility Name
Royal Marsden Hospital
City
London
ZIP/Postal Code
SW3 6JJ
Country
United Kingdom
Facility Name
Kent Oncology Centre
City
Maidstone
ZIP/Postal Code
ME16 9QQ
Country
United Kingdom
Facility Name
Christie Hospital Manchester
City
Manchester
ZIP/Postal Code
M20 4BX
Country
United Kingdom
Facility Name
Wythenshawe Hospital Manchester
City
Manchester
ZIP/Postal Code
M23 9LT
Country
United Kingdom
Facility Name
Wrexham Maelor Hospital
City
Wrexham
ZIP/Postal Code
LL13 7TD
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
15118125
Citation
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 4;304(5676):1497-500. doi: 10.1126/science.1099314. Epub 2004 Apr 29.
Results Reference
background
PubMed Identifier
22285168
Citation
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Munoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Francais de Pneumo-Cancerologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.
Results Reference
background
PubMed Identifier
15728811
Citation
Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005 Feb 24;352(8):786-92. doi: 10.1056/NEJMoa044238.
Results Reference
background
Citation
Kabbinavar F, Miller VA, Johnson BE, O'Connor P, Soh C-H, ATLAS Investigators. Overall survival in ATLAS, a Phase IIIb trial comparing bevacizumab therapy +/- erlotinib after completion of chemotherapy with bevacizumab for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28 (May suppl; abstr 7526).
Results Reference
background
PubMed Identifier
28408243
Citation
Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massuti B, Palmero R, Aix SP, Carcereny E, Fruh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gomez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative group. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2017 May;5(5):435-444. doi: 10.1016/S2213-2600(17)30129-7. Epub 2017 Apr 10. Erratum In: Lancet Respir Med. 2018 Dec;6(12):e57.
Results Reference
derived

Learn more about this trial

BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)

We'll reach out to this number within 24 hrs